Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Molecular signaling in breast cancer (CROSBI ID 517293)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Levanat, Sonja ; Musani, Vesna ; Levačić Cvok, Mirela ; Čretnik, Maja Molecular signaling in breast cancer // Book of abstracts : XIV S.I.S. World congress on breast diseases / Drinković, Ivan (ur.). Zagreb: Medimond International Proceedings, 2006. str. 7-12

Podaci o odgovornosti

Levanat, Sonja ; Musani, Vesna ; Levačić Cvok, Mirela ; Čretnik, Maja

engleski

Molecular signaling in breast cancer

Breast cancer tumorigenesis is a multistep process in which the normal breast epithelium evolves via hyperplasia and carcinoma in situ into an invasive cancer , which eventually can disseminate via lymph and blood vascular system to form metastases. Each of these steps is thought to correlate with one or more distinct mutations in major regulatory genes. These genes play a role in maintaining balance between proliferation, apoptosis and differentiation, while other genes regulate expression of steroid receptors, cell adhesion molecules and angiogenic factors, and of various other proteins important for invasion and establishment of metastases. Hereditary breast cancer is characterized by an inherited susceptibility to breast cancer on basis of an identified germline mutation in one allele of a high penetrance susceptibility genes (such as BRCA 1 and 2, p53), which are acting as tumor suppressors. Sporadic breast cancers result from serial accumulation of acquired and uncorrected mutations, with mutational activation of oncogenes ( Myc, CCND1, HER-2/neu), often coupled with non- or mutational inactivation of tumor suppressor genes (p53). In both in hereditary and in sporadic cancer, early event can take place in a variety of specific genes, leading through different pathways, probably to different tumour types, which have a different clinical outcome. However, non-mutational functional suppression could result from various epigenetic mechanisms, i.e. impaired DNA methylation. Knowledge of different tumor development pathways, each starting from distinct and specific early event leading to specific clinically relevant subtype of tumours, would be of value for the clinics.

breast cancer ; tumors ; signaling

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

7-12.

2006.

objavljeno

Podaci o matičnoj publikaciji

Book of abstracts : XIV S.I.S. World congress on breast diseases

Drinković, Ivan

Zagreb: Medimond International Proceedings

Podaci o skupu

XIV S.I.S. World congress on breast diseases

pozvano predavanje

18.05.2006-21.05.2006

Zagreb, Hrvatska

Povezanost rada

Temeljne medicinske znanosti